Status:

COMPLETED

ADME Study of [14C]ICP-022 in Healthy Males

Lead Sponsor:

Beijing InnoCare Pharma Tech Co., Ltd.

Conditions:

Healthy Volunteers

Eligibility:

MALE

18-45 years

Phase:

NA

Brief Summary

The purpose of this study is to investigate the absorption, the metabolic pathways and the excretion of ICP-022 in healthy male adult participants after administration of a single oral dose of 150 mg ...

Eligibility Criteria

Inclusion

  • key Inclusion criteria:
  • Weight: Body mass index (BMI) is 19\~26 kg/m2
  • signing of informed consent
  • Volunteers are able to communicate well with the investigators and be able to complete the trial according to the process
  • Key Exclusion Criteria:
  • physical examination, vital signs, routine laboratory tests (blood routine, blood biochemistry, blood coagulation routine, urine routine, stool routine + occult blood, serum amylase, thyroid function, etc.), 12-lead ECG, Chest X-ray (Anteroposterior), abdominal B-ultrasound (hepatobiliary, pancreas, spleen and kidney) and other abnormalities and clinical significance.
  • ophthalmologic examination shows abnormality and clinical significance
  • Positive test for hepatitis B (surface antigens HBs), or C (antibody HCs), positive test for HIV, positive test for Syphilis antibody.
  • Within 1 month before the screening, having not limited to known as hepatic enzyme inducers, inhibitors or substrates; (eg, inducer - barbiturate, carbamazepine, phenytoin, rifampicin, dexamethasone, rifabutin, rifapentine; inhibitors - SSRI antidepressants, cimetidine, diltiazem, macrolides, verapamil, imidazole antifungals) ;
  • Within 1 month before the screening, receiving the anticoagulant therapy such as warfarin or thrombin inhibitor and/or aspirin antiplatelet therapy
  • NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Exclusion

    Key Trial Info

    Start Date :

    July 1 2019

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    August 6 2019

    Estimated Enrollment :

    6 Patients enrolled

    Trial Details

    Trial ID

    NCT04441450

    Start Date

    July 1 2019

    End Date

    August 6 2019

    Last Update

    June 22 2020

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    The First Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China